HBI Deals+Insights / News
Listed dialysis, pharma and hospital group Fresenius has seen a 6% jump in its share price after 2019 results were better than some analysts expected. But with significant Asia exposure in certain businesses, CEO Stephan Sturm says: "Coronavirus is not going to be a positive for us."